News & Insights

TAMPA, Fla. (Sept. 22, 2025) — Moffitt Cancer Center, a national leader in cancer research and treatment, announced today the launch of AccelerOnc Studio, the first venture studio in the United States solely dedicated to oncology innovation. The initiative aims to translate clinical, scientific and technological expertise within health systems, beginning with Moffitt, into scalable solutions that improve outcomes for cancer patients worldwide.

AccelerOnc Studio will focus on identifying unmet clinical needs and commercializing intellectual property developed within health systems and cancer centers, starting with Moffitt’s own. By fostering early stage ventures rooted in real-world insights from frontline care and research, AccelerOnc is positioned to radically accelerate the path from innovation to impact in oncology.

“The launch of AccelerOnc Studio is a significant step in our mission to contribute bold breakthroughs in cancer research and care,” said Patrick Hwu, M.D., president and CEO of Moffitt. “This venture studio strengthens our ability to bring Moffitt’s expertise and innovations to cancer patients around the world and supports our strategy to lead in a new era where digital technologies and artificial intelligence are transforming how we understand and treat cancer.”

AccelerOnc will initially incubate companies based on Moffitt’s pipeline of ideas and intellectual property, then expand to include partners across the broader oncology ecosystem. The studio’s focus will span digital health, artificial intelligence and data-driven platforms, all aimed at advancing cancer care.

“AccelerOnc has the essential ingredients for success,” said Xavier Avat, chief business officer of Moffitt. “We have the support of a world-class institution in Moffitt, the entrepreneurial leadership of Dr. Kamal Jethwani, an experienced physician executive with a proven track record in health innovation, and a strong pipeline of intellectual property generated by our faculty every day. This combination of infrastructure, talent and scientific discovery positions AccelerOnc to reshape the future of oncology innovation.”

“The companies we’re incubating represent the kind of bold thinking that defines AccelerOnc Studio,” said Kamal Jethwani, M.D., leader of AccelerOnc Studio. “We’re leveraging Moffitt’s unparalleled clinical data, analytical power and deep clinical expertise to build ventures that can truly scale. One incubation is focused on delivering Moffitt’s clinical excellence to patients globally through a fully digital, dematerialized care model. Another aims to develop the world’s first AI-powered oncologist, an intelligent system trained on real clinical decisions to support diagnosis, treatment planning and precision oncology at scale. These are the kinds of breakthroughs we believe will redefine the future of cancer care.”

About Moffitt Cancer Center

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer.

The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-844-615-9372), visit MOFFITT.org, and follow the momentum on Facebook, X, Instagram and YouTube.

About AccelerOnc

Founded by Moffitt Cancer Center, AccelerOnc Studio is a venture studio focused on developing new solutions for cancer care through early stage companies built on intellectual property from leading health systems. AccelerOnc supports ventures in digital health and artificial intelligence aimed at improving outcomes for patients globally. The studio connects clinical insights and entrepreneurial leadership to help shape the future of oncology innovation. For more information, please visit www.acceleronc.com, and follow the momentum on LinkedIn.

For more information, contact:

Kim Polacek

813-504-9706

Kim.Polacek@Moffitt.org